What do these items mean when the immunohistochemistry report helps analyze the immunohistochemistry

This is only the result of immunohistochemistry and cannot be used as a diagnosis alone, but it can be used in combination with microscopic structural changes for diagnosis and differential diagnosis. If you are taking a biopsy of a lymph node or nasal tissue, based on my diagnostic experience, the following can be explained:

Low-grade moderately aggressive B-cell non-Hodgkin lymphoma,** which is activated B cells that are not germinal centers.

CD56 perforin- tia- granzymeb- can rule out extranodal NK T-cell lymphoma (from these indicators are like nasal tissue biopsy); CD21- excludes follicular dendritic tumors and confirms absence of FDC reticulum dilation, thereby also excluding FL and marginal zone B-cell lymphomas; CKP- excludes carcinoma of the epithelium**; CD20+++ confirmed to be of B-cell origin; EBV- excludes age-related EBV-related diffuse large B-cell lymphoma. The only thing that makes people wonder is that lamda++ kappa+ are both positive, which does not conform to monoclonal hyperplasia; 50% of KI-67 indicates low proliferative activity and can exclude many high-malignant lymphoma subtypes.

I don't understand this, I'm not studying medicine.

CD3(-) malignant lymphomas include non-Hodgkin lymphoma that is CD3 positive.

CD20(+) non-Hodgkin lymphoma CD20 positive.

CD21 (fdc mesh shrinkage) is positive for diffuse large B-cell lymphoma.

CD30(-) Hodgkin lymphoma CD30 positive.

KI67 (80 positive): proliferative index, the higher the malignancy.

BCL-2(+) Burkitt lymphoma positive.

BCL-6 (+ positive for Burkitt lymphoma.

MUML(+) germinal center B-cell lymphoma positive.

PAX-5(+) is positive for diffuse large B-cell lymphoma.

CD10(+) small B-cell lymphoma is CD10 positive.

C-MYC (40 positive) C-MYC is positive, indicating a high degree of malignancy.

Conclusion, diffuse large B-cell lymphoma. Chemotherapy and radiotherapy are required after surgery. Should be able to **.

The surgically resected tissue is finally known to be benign or malignant through the results of pathological examination, but in the end, the most accurate must wait for the results of immunohistochemistry to come out before daring to make a conclusion, which is generally a report issued by the doctor of the pathology department of the hospital, and the attending doctor may not be able to understand it if he does not study the pathology.

Question: Can you tell if it is highly differentiated or underdifferentiated?

Solid adenocarcinoma is poorly differentiated.

Acinar and adherent are highly differentiated.

Question: Is the problem of low differentiation more serious than the problem of high differentiation?

Spread faster, huh?

Question: In a case like the one I posted, I have undergone surgery, chemotherapy and radiotherapy, is it possible to follow up**?

Two metastases have been seen in 11 groups of lymph nodes.

Question: Is this early, middle, or late?

Wait a minute, I'll take a look.

Radiotherapy is still recommended for lymph node metastasis, local radiotherapy on the affected side can reduce the risk, and the specific radiotherapy area can consult a breast specialist or radiotherapy doctor in a regular hospital, and the right radiotherapy has no effect on the heart, and the radiotherapy is small.

If CK and CEA are positive, it is considered adenocarcinoma;

HER2 positive, not suitable for targeting**;

KI67 was strongly positive, indicating that cancer cells were actively proliferating and had a high degree of malignancy.

Summary. Dear Greetings Lord, I am Mr. Xiao Xin, I am very happy with your question, it takes time to type, your question within five minutes, please be patient

Dear Hello to the main impulse, I am Teacher Xiao Xin, I am very happy for you to ask the question of Sanmingyuan, it takes time to type, Huaizhi will have your question within five minutes, please be patient

How to look at the results of immunohistochemistry Guo Yanyan, Chief Technician, Department of Clinical Laboratory, Tangshan Workers Hospital The results of the top three immunohistochemistry are often based on these aspects: The epithelial marker ck pan is positive, indicating that the tumor tissue originates from the epithelial tissue, and if it is a malignant tumor, it is cancer; A positive mesenchymal tissue marker vimentin indicates that the tumor tissue originates from the mesenchymal tissue, and if it is a malignant tumor, it is a sarcoma; Neurological and neuroendocrine markers: CGA, SYN, NSE, CD99, elevated NSE is a specific marker for small cell carcinoma; Lymphocyte markers:

LCA and TDT for the diagnosis of lymphatic mask Qingyuan tumor; Ki67 indicates the degree of proliferation activity of cells. The clinical application of immunohistochemistry mainly includes the following aspects: diagnosis and differential diagnosis of malignant tumors; Determine the primary site of metastatic malignancy; further pathologic classification of a certain type of tumor; The ** of soft tissue tumors generally needs to be classified according to the correct histology, because of their many species differences and similar tissue morphology, it is sometimes difficult to distinguish their tissues, and the use of a variety of markers for the diagnosis of soft tissue tumors is indispensable; The discovery of micrometastases is helpful in the determination of the clinical protocol, including the determination of the scope of surgery.

According to the results of immunohistochemistry, the best protocol is provided for clinical practice.

Immunological group hail balancing test. Rapid cap membrane temperature control alone is a special operation method in the process of immunohistochemistry. The cost of immunohistochemistry is relatively high.

Immunohistochemistry plays an irreplaceable role in the diagnosis and development of lung cancer. It is inseparable when waiting for the diagnosis of whether it is really cancerous, it is also needed when observing whether it is successful, and it is still indispensable when the prognosis is differentiated. Therefore, it is not too much to compare the results of immunohistochemistry to a judgment of the patient.

For patients and their families, immunohistochemistry results often seem too professional to confuse people's heads, and they have to go through the trouble to consult a doctor over and over again. There are also some patients who feel that immunohistochemistry is similar to genetic testing, and it is enough to do one. So today, let's talk to you about immunohistochemistry.

Hello, it is a pleasure to serve you and give you the following answer: Immunohistochemistry only gives three data results because it is a technology that can be used to detect a specific antigen instead of detecting all antigens. Thus, there are three data results that can provide information about a particular antigen.

The solution to this problem is to use a variety of techniques to detect more antigens. For example, techniques such as immunohistochemistry, western blotting, mass spectrometry, fluorescence immunodetection, etc., can be used to detect more antigens. Steps:

1.First of all, you need to prepare the required samples, such as cells, tissues, antigens, antibodies, etc. 2.

Then, different techniques such as immunohistochemistry, western blotting, mass spectrometry, fluorescence immunoassays, etc., are used to detect the antigen. 3.Finally, according to the test results, the expression of antigens and the relationship between antigens were analyzed.

Personal tips: When using immunohistochemistry, you should pay attention to the selection of antibodies to ensure that antibodies can effectively detect antigens. In addition, when using other techniques, attention should also be paid to sample preparation to ensure accurate detection of antigens.